Vanda Pharmaceuticals Inc Asset Resilience Ratio
Vanda Pharmaceuticals Inc asset resilience ratio. Vanda Pharmaceuticals Inc (VNDA) has an Asset Resilience Ratio of 36.61% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See VNDA days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Vanda Pharmaceuticals Inc (2005–2025)
Asset resilience ratio of Vanda Pharmaceuticals Inc from 2005 to 2025. This chart shows how Vanda Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read debt load of Vanda Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Vanda Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see VNDA total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $179.00 Million | 36.61% |
| Total Liquid Assets | $179.00 Million | 36.61% |
Asset Resilience Insights
- Very High Liquidity: Vanda Pharmaceuticals Inc maintains exceptional liquid asset reserves at 36.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Vanda Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Vanda Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Vanda Pharmaceuticals Inc Asset Resilience Ratio by Year (2005–2025)
Vanda Pharmaceuticals Inc asset resilience ratio by year from 2005 to 2025. The table below shows the annual Asset Resilience Ratio data for Vanda Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 36.61% | $179.00 Million | $488.95 Million | -4.89pp |
| 2024-12-31 | 41.50% | $272.33 Million | $656.20 Million | +2.57pp |
| 2023-12-31 | 38.93% | $252.44 Million | $648.44 Million | -13.39pp |
| 2022-12-31 | 52.32% | $331.83 Million | $634.25 Million | -11.80pp |
| 2021-12-31 | 64.12% | $380.74 Million | $593.79 Million | +6.63pp |
| 2020-12-31 | 57.49% | $306.71 Million | $533.46 Million | +2.29pp |
| 2019-12-31 | 55.21% | $267.06 Million | $483.75 Million | -3.91pp |
| 2018-12-31 | 59.12% | $196.35 Million | $332.13 Million | +5.68pp |
| 2017-12-31 | 53.44% | $109.79 Million | $205.43 Million | +5.47pp |
| 2016-12-31 | 47.97% | $100.91 Million | $210.37 Million | +4.63pp |
| 2015-12-31 | 43.34% | $92.34 Million | $213.05 Million | +3.20pp |
| 2014-12-31 | 40.14% | $68.92 Million | $171.70 Million | -5.61pp |
| 2013-12-31 | 45.75% | $65.59 Million | $143.35 Million | +22.40pp |
| 2012-12-31 | 23.35% | $31.63 Million | $135.45 Million | -10.03pp |
| 2011-12-31 | 33.38% | $60.96 Million | $182.62 Million | -39.58pp |
| 2010-12-31 | 72.96% | $155.48 Million | $213.10 Million | +58.18pp |
| 2008-12-31 | 14.78% | $7.38 Million | $49.93 Million | -29.87pp |
| 2007-12-31 | 44.65% | $43.24 Million | $96.86 Million | +42.05pp |
| 2006-12-31 | 2.60% | $941.98K | $36.26 Million | -25.77pp |
| 2005-12-31 | 28.36% | $10.14 Million | $35.75 Million | -- |
About Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nightt… Read more